Stromal resistance of fibroblasts against oxidative damage: Involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 404-410

  Werth, Christel ^a   Stuhlmann, Dominik ^a   Cat, Bahar ^a   Steinbrenner, Holger ^a   Alili, Lirija ^a   Sies, Helmut ^a   Brenneisen, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MICROENVIRONMENT; OXIDATIVE STRESS; PARACRINE SIGNALING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SKIN CELL; STROMA CELL; SUPERNATANT; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED, 80 AND OVER; ANTIOXIDANTS; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS; OXIDATIVE STRESS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 40549138777     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm296     Document Type: Article

References (67)

1. de Wever,O. et al. (2003) Role of tissue stroma in cancer cell invasion. J. Pathol., 200, 429-447.
2. Bhowmick,N.A. et al. (2005) Tumor-stroma interactions. Curr. Opin. Genet. Dev., 15, 97-101.
3. Liotta,L.A. et al. (2001) The microenvironment of the tumour-host interface. Nature, 411, 375-379.
4. Cat,B. et al. (2006) Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J. Cell Sci., 119, 2727-2738.
5. Kalluri,R. et al. (2066) Fibroblasts in cancer. Nat. Rev. Cancer, 6, 392-401.
6. Lazar-Molnar,E. et al. (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12, 547-554.
7. Gotzmann,J. et al. (2006) A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene, 25, 3170-3185.
8. Stuhlmann,D. et al. (2004) Paracrine effect of TGF-beta1 on downregulation of gap junctional intercellular communication between human dermal fibroblasts. Biochem. Biophys. Res. Commun., 319 321-326.
9. de Wever,O. et al. (2002) Role of myofibroblasts at the invasion front. Biol. Chem., 383, 55-67.
10. Maher,E.A. et al. (2001) Malignant glioma: Genetics and biology of a grave matter. Genes Dev., 15, 1311-1333.
11. Yoeli-Lerner,M. et al. (2006) Akt/PKB signaling in cancer: A function in cell motility and invasion. Cell Cycle, 5, 603-605.
12. Servidei,T. et al. (2006) Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J. Cell. Physiol., 208, 220-228.
13. Ueda,S. et al. (2006) PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res., 66, 5346-5353.
14. Davies,M. et al. (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J. Cell. Biochem. 95, 918-931.
15. Kunz-Schughart,L.A. et al. (2002) Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol. Histopathol. 17, 623-637.
16. Bayreuther,K. et al. (1992) Terminal differentiation, aging, apoptosis, and spontaneous transformation in fibroblast stem cell systems in vivo and in vitro. Ann. N. Y. Acad. Sci., 663 167-179.
17. Giard,D.J. et al. (1973) In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J. Natl Cancer Inst., 51, 1417-1423.
18. Boukamp,P. et al. (1982) Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin. J. Natl Cancer Inst., 68, 415-427.
19. Glade,C.P. et al. (1996) Multiparameter flow cytometric characterization of epidermal cell suspensions prepared from normal and hyperproliferative human skin using an optimized thermolysin-trypsin protocol. Arch. Dermatol. Res., 288, 203-210.
20. Green,L.M. et al. (1984) Rapid colorimetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokines. J. Immunol. Methods, 70, 257-268.
21. Laemmli,U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
22. Sies,H. et al. (1985) Oxidative stress: Damage to intact cells and organs. Philos. Trans. R. Soc. Lond., B, Biol. Sci., 311, 617-631.
23. Sies,H. (1986) Biochemistry of oxidative stress. Angew. Chem. Int. Ed. Engl., 25, 1058-1071.
24. Zivkovic,M. et al. (2007) Oxidative burst of neutrophils against melanoma B16-F10. Cancer Lett., 246, 100-108.
25. Lopez-Lazaro,M. (2007) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett., 252, 1-8.
26. Stuhlmann,D. et al. (2003) Modulation of homologous gap junctional intercellular communication of human dermal fibroblasts via a paracrine factors generated by squamous tumor cells. Carcinogenesis, 24 1737-1748.
27. Datta,S.R. et al. (1999) Cellular survival: A play in three Akts. Genes Dev., 13, 2905-2927.
28. Song,G. et al. (2005) The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med., 9, 59-71.
29. Persad,S. et al. (2001) Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: Critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 276, 27462-27469.
30. Carpenter,C.L. et al. (1996) Phosphoinositide kinases. Curr. Opin. Cell Biol., 8, 153-158.
31. Coffey,R.J.Jr et al. (1987) Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol. 132, 143-148.
32. Stein,C.A. et al. (1989) Suramin: An anticancer drug with a unique mechanism of action. J. Clin. Oncol., 7, 499-508.
33. Kopp,R. et al. (1990) Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res., 50, 6490-6496.
34. Gonzalez-Rubio,M. et al. (1996) Oxidative stress induces tyrosine phosphorylation of PDGF alpha-and beta-receptors and pp60c-src in mesangial cells. Kidney Int., 50, 164-173.
35. Levitzki,A. (1999) Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther., 82, 231-239.
36. Banai,S. et al. (1998) PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation, 97, 1960-1969.
37. Fishbein,I. et al. (2000) Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J. Control. Release, 65, 221-229.
38. Steinbrenner,H. et al. (2006) Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic. Biol. Med., 40, 1513-1523.
39. Toussaint,O. et al. (1993) Relationship between the critical level of oxidative stresses and the glutathione peroxidase activity. Toxicology, 81, 89-101.
40. Behrend,L. et al. (2003) Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans., 31, 1441-1444.
41. Thannickal,V.J. et al. (2000) Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol., 279, L1005-L1028.
42. Jones,D.P. (2006) Redefining oxidative stress. Antioxid. Redox Signal., 8, 1865-1879.
43. Sies,H. (1991) Oxidative stress: From basic research to clinical application. Am. J. Med., 91, 31S-38S.
44. Schumacker,P.T. (2006) Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell, 10, 175-176.
45. Trachootham,D. et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 10, 241-252.
46. Alexandre,J. et al. (2007) Novel action of paclitaxel against cancer cells: Bystander effect mediated by reactive oxygen species. Cancer Res., 67, 3512-3517.
47. Bhosle,S.M. et al. (2005) Enhancement of radiation-induced oxidative stress and cytotoxicity in tumor cells by ellagic acid. Clin. Chim. Acta, 359, 89-100.
48. Pervaiz,S. et al. (2004) Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? Curr. Pharm. Des. 10, 1969-1977.
49. Birnbaum,A. et al. (2005) Gefitinib therapy for non-small cell lung cancer. Curr. Treat. Options Oncol., 6, 75-81.
50. Thomas,A.L. et al. (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: Report of a phase I/II dose-escalating study. Eur J. Cancer, 36, 2329-2334.
51. Lee,H.C. et al. (2004) Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. Int. J. Mol. Med., 13, 883-887.
52. Sun,J. et al. (1998) Role of antioxidant enzyme on ionizing radiation resistance. Free Radic. Biol. Med., 24, 586-592.
53. Mochizuki,T. et al. (2006) Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene, 25, 3699-3707.
54. Rodriguez-Mora,O.G. et al. (2006) Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol. Ther., 5, 1022-1030.
55. Tozeren,A. et al. (2005) Origins and evolution of cell phenotypes in breast tumors. J. Theor Biol., 233, 43-54.
56. Heldin,C.H. et al. (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev., 79, 1283-1316.
57. Shamah,S.M. et al. (1993) Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol. Cell. Biol., 13, 7203-7212.
58. Barnhill,R.L. et al. (1996) Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br. J. Dermatol., 135, 898-904.
59. Lederle,W. et al. (2006) Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. Am. J. Pathol., 169, 1767-1783.
60. Manning,B.D. et al. (2007) AKT/PKB signaling: Navigating downstream. Cell, 129, 1261-1274.
61. Mawrin,C. et al. (2005) Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin. Cancer Res., 11, 4074-4082.
62. Robertson,G.P. (2005) Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev., 24 273-285.
63. Rosenmuller,T. et al. (2001) Role of phosphoinositide 3OH-kinase in autocrine transformation by PDGF-BB. J. Cell. Physiol., 188 369-382.
64. Hotfilder,M. et al. (2005) PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br. J. Cancer, 92, 705-710.
65. Sen,P. et al. (2006) Tea polyphenol epigallocatechin 3-gallate impedes the anti-apoptotic effects of low-grade repetitive stress through inhibition of Akt and NFkappaB survival pathways. FEBS Lett. 580, 278-284.
66. Gao,Z. et al. (2005) Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J. Biol. Chem., 280, 9375-9389.
67. Ho,H.Y. et al. (2006) Green tea polyphenol epigallocatechin-3-gallate protects cells against peroxynitrite-induced cytotoxicity: Modulatory effect of cellular G6PD status. J. Agric. Food Chem., 54, 1638-1645.